At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 71 enrolled
Drug / intervention
Cinacalcetdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management
In Brief
A Phase 4 clinical trial evaluating Cinacalcet for Anemia and Secondary Hyperparathyroidism. Completed, enrolled 71 participants.
Detailed Summary
The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Secondary Hyperparathyroidism
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedFeb 2007
Primary CompletionJun 2009
Study CompletionOct 2009
TodayJul 2026
First PostedFeb 5, 2007
Enrollment StartSep 1, 2006
Primary CompletionJun 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.4 years ago
Interventions
Cinacalcetdrug
Cinacalcet tablets